MedTrace Logo

A Study of a New Investigational Medicinal Product to Treat Patients with Advanced or Metastatic Solid Tumors

NCT03316638 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 316

Last updated 2024-12-10

No results posted yet for this study

Summary

W0101 combines a cytotoxic compound to a monoclonal antibody targeting a receptor commonly overexpressed in many cancers.

The development of antibody-drug conjugates takes advantage of the specificity of the mAb while augmenting its ability to produce a cytotoxic effect. The expected benefits of antibody-drug conjugation are enhancement of cytotoxicity in target cells and limiting toxicities of cytotoxic drugs in normal tissues.

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

DRUG

W0101 - Cohort A1

Administered once every 2 weeks

DRUG

W0101 - Cohort A2

Administered every 3 weeks

DRUG

W0101 - Expansion Phase

Administered according to the recommended dose for expansion

Sponsors & Collaborators

  • Pierre Fabre Medicament

    lead INDUSTRY

Principal Investigators

  • Eric Chetaille, MD · Pierre Fabre Medicament

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-24
Primary Completion
2021-10-30
Completion
2022-07-05

Countries

  • France
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03316638 on ClinicalTrials.gov